The Food and Drug Administration’s rejection of a gene therapy for hemophilia A on Wednesday surprised many hematology researchers and Wall Street watchers who expected speedy approval for the one-time treatment to end the inherited bleeding disorder.
For one family in Indianapolis active in the hemophilia patient community, the decision was disappointing, but also appreciated.
About the Author Reprints
